Share on StockTwits

Investment analysts at Wells Fargo & Co. assumed coverage on shares of Immune Design Corp (NASDAQ:IMDZ) in a note issued to investors on Monday, reports. The firm set an “outperform” rating on the stock.

Separately, analysts at Jefferies Group initiated coverage on shares of Immune Design Corp in a research note on Monday. They set a “buy” rating and a $15.00 price target on the stock.

Immune Design Corp (NASDAQ:IMDZ) opened at 12.41 on Monday. Immune Design Corp has a 52-week low of $11.51 and a 52-week high of $12.81. The stock has a 50-day moving average of $12.12 and a 200-day moving average of $12.12. The company’s market cap is $195.7 million.

Immune Design Corp is a clinical-stage immunotherapy company. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (NASDAQ:IMDZ), to fight cancer.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.